Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

[1]  Lara A. Kahale,et al.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2021, The Cochrane database of systematic reviews.

[2]  M. Weller,et al.  Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas , 2017, Oncotarget.

[3]  P. Fisher,et al.  Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin , 2016, Proceedings of the National Academy of Sciences.

[4]  D. Kondziolka,et al.  Mutant IDH1 and thrombosis in gliomas , 2016, Acta Neuropathologica.

[5]  R. Stupp,et al.  Corticosteroids compromise survival in glioblastoma. , 2016, Brain : a journal of neurology.

[6]  M. Gilbert,et al.  Venous thromboembolism (VTE) and glioblastoma , 2015, Journal of Neuro-Oncology.

[7]  T. Mikkelsen,et al.  Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. , 2015, Neuro-oncology.

[8]  E. Antonarakis,et al.  The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. , 2015, Clinical genitourinary cancer.

[9]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[10]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[11]  H. Tsuchiya,et al.  Low molecular weight heparin suppresses receptor for advanced glycation end products‐mediated expression of malignant phenotype in human fibrosarcoma cells , 2013, Cancer science.

[12]  M. Malkin,et al.  PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma , 2010, Journal of thrombosis and haemostasis : JTH.

[13]  S. Mousa,et al.  Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence , 2009, Thrombosis and Haemostasis.

[14]  A. Friedman,et al.  Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients , 2009, Journal of Neuro-Oncology.

[15]  M. Gilbert,et al.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial , 2008, Cancer Chemotherapy and Pharmacology.

[16]  A. Khorana,et al.  A meta‐analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment , 2007, Cancer.

[17]  A. Khorana,et al.  A meta-analysis of anticoagulants as cancer treatment: Impact on survival and bleeding complications , 2007 .

[18]  D. Henry,et al.  The mechanism of low molecular weight heparin (LMWH) inhibition of tumor growth. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Mousa,et al.  Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor , 2004, Thrombosis and Haemostasis.

[20]  A Rimner,et al.  Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. , 2001, Cancer research.

[21]  Susanne M. Smorenburg,et al.  Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. , 2000, Cancer research.

[22]  W. Geerts,et al.  The risk of venous thromboembolism is increased throughout the course of malignant glioma , 2000, Cancer.

[23]  A. Khorana,et al.  Recurrent venous thromboembolism in glioblastoma. , 2016, Thrombosis research.

[24]  Lara A. Kahale,et al.  Parenteral anticoagulation in ambulatory patients with cancer. , 2014, The Cochrane database of systematic reviews.

[25]  Lara A. Kahale,et al.  Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, The Cochrane database of systematic reviews.

[26]  A. Varki,et al.  Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. , 2007, Thrombosis research.